DOPAMINERJIK SİSTEM VE BAĞIMLILIK

Uzbay İT. Nöropsikofarmakoloji, Rasyonel İlaç Kullanımı. Yorum Yayıncılık& İstanbul Tıp Kitabevi 2007,-147-155.

Koob GF. The neurobiology of addiction: a neuroadaptatîonal view relevant for diagnosis. Addiction. 2006,101 (Suppl 1):23-30.

Di Chiara G, Bassareo V. Reward system and addiction: what dopamine does and doesn't do. Curr Opin Pharmacol. 2007;7:69-76.

Franken IH, Booij J, van den Brink W. The role of dopamine in human addiction: from reward to motivated attention. Eur J Pharmacol. 2005;526:199-206.

Kalivas PW. Recent understanding in the mechanisms of addiction. Curr. Psychiatry Rep. 2004;6:347-351

Köhnke MD. Approach to the genetics of alcoholism: a review based on pathophysiology. Biochem Pharmacol. 2008;75:160-177.

Renthal W, Nesiler EJ. Epigenetic mechanisms in drug addiction. Trends mol med. 2008;14:341-3 50.

Uzbay IT. Madde Bağımlılığı ve Dopaminerjik Sistem. Türkiye Klinikleri Dahili Tıp Bilimleri Dergisi Psikiyatri 2005;47:65-72

Wise RA, Bozarth MA. A psychomotor stimulant theory of addiction. Psychol. Rev. 1987;94:469-492.

Barrett SP, Boileau I, Okker J, et al. The hedonic response to cigarette smoking is proportional to dopamine release in the human striatum as measured by positron emission tomography and [(11)0 raclopride. Synapse 2004;54;65-71.

Volkow ND, Fowler JS, Wang GJ, et al. Dopamine in drug abuse and addiction: results of imaging studies and treatment implications. Arch Neurol. 2007;64:1575-9.

Oswald EM, Wong DF, McCaul M, et al. Relationships among ventral striatal dopamine release, cortisol secretion, and subjective responses to amphetamine. Neuropsychopharmacology 2005;30, 821-832.

Volkow ND, Wang GJ, Fowler JS, et al. Brain DA D2 receptors predict reinforcing effects of stimulants in humans: replication study. Synapse. 2002;46:79-82.

Sienkiewicz-Jarosz H, Scinska A, Kuran W, et al. Taste responses in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 2005;76:40-46.

Brauer LH, De Wit H. High dose pimozide does not block amphetamine-induced euphoria in normal volunteers. Pharmacol Biochem Behav 1997;56:265-272

Leyton M, Casey KF, Delaney JS, et al. Cocaine craving, euphoria, and selfadministration: a preliminary study of the effect of catecholamine precursor depletion. Behav Neurosci 2005; 119:1619-1627

Berridge KC. The debate over dopamine's role in reward: the case for incentive salience. Psychopharmacology (Berl). 2007;191:391-431.

Volkow ND, Fowler JS, Wang GJ. The addicted human brain: insights from imaging studies. J. Clin. Invest. 2003;! 11,1444-1451.

Nestler EJ. Molecular mechanisms of drug addiction. Neuropharmacology 2004;47:24-32.

Robinson TE, Berridge KC. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res. Rev. 1993,18, 247-291.

Yasuno F, Ota M, Ando K, et al. Role of ventral striatal dopamine D1 receptor in cigarette craving. Biol Psychiatry. 2007;61:1252-9.

Zijlstra F, Booij J, van den Brink W, et al. Striatal dopamine D2 receptor binding and dopamine release during cue-elicited craving in recently abstinent opiate-dependent males. Eur Neuropsychopharmacol. 2008;18:262-70.

Soares BG, Lima MS, Reisser AA, et al. Dopamine agonists for cocaine dependence. Cochrane Database Syst Rev. 2003;2:1-45.

Soyka M, De Vry J. Flupenthixol as a potential pharmacotreatment of alcohol and cocaine abuse/dependence. Eur Neuropsychopharmacol. 2000; 10:325-32.

Amato L, Minozzi S, Pani PP, et al. Antipsychotic medications for cocaine dependence. Cochrane Database Syst Rev. 2007; 18:1-28.

Martinotti G, DI Nicola M, Di Giannantonio M, et al. Aripiprazole in the treatment of patients with alcoholdependence:adouble-blind, comparison trial vs. Naltrexone. J Psychopharmacol. 2008 doi: 10.1177/0269881108089596.

Franken IH, Stam CJ, Hendriks VM, et al. Neurophysiological evidence for abnormal cognitive processing of drug cues in heroin dependence. Psychopharmacology 2003;170,205-212.

Franken IH, Hendriks VM, Stam CJ, et al. A role for dopamine in the processing of drug cues in heroin dependent patients. Eur. Neuropsychopharmacol. 2004;14, 503-508.

Marissen MA, Franken IH, Waters AJ, et al Attentionalblaspredictsheroin relapse following treatment. Addiction. 2006;101:1306-12.

Blum K, Sheridan PJ, Wood RC, et al. The D2 dopamine receptor gene as a determinant of reward deficiency syndrome. J R Soc Med. 1996;89:396-400.

Smith L, Watson M, Gates S, et al. MetaAnalysis of the Association of the Taq1A Polymorphism with the Risk of Alcohol Dependency: A HuGE Gene-Disease Association Review. Am J Epidemiol 2008;167:125-138

Shahmoradgoli Najafabadi M, Ohadi M, et al. Association between the DRD2 A1 allele and opium addiction in the Iranian population. Am J Med Genet B Neuropsychiatr Genet. 2005;1346:39-41.

Erblich J, Lerman C, Self DW, et al. Stress-induced cigarette craving: effects of the DRD2 Taql RFLP and SLC6A3 VNTR polymorphisms. Pharmacogenomics J. 2004;4:102-9.

Haile CN, Kosten TR, Kosten TA. Genetics of dopamine and its contribution to cocaine addiction. Behav Genet. 2007;37:119-45.

Shao C, Li Y, Jiang K, et al. Dopamine D4 receptor polymorphism modulates cue-elicited heroin craving in Chinese. Psychopharmacology (Berl). 2006;186:185-90.

Franklin TR, Lohoff FW, Wang Z, et al. DAT genotype modulates brain and behavioral responses elicited by cigarette cues. Neuropsychopharmacology. 2009,34:717-28.

Schmidt LG, Harms H, Kuhn S, et al. Modification of alcohol withdrawal by the A9 allele of the dopamine transporter gene. Am J Psychiatry 1998; 155:474-478.

Kreek MJ, Bart G, Lilly C, et al. Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments. Pharmacol Rev. 2005;57:1-26.

UJike H, Harano M, Inada T, et al. Nine- or fewer repeat alleles in VNTR polymorphism of the dopamine transporter gene is a strong risk factor for prolonged methamphetamine psychosis. Pharmacogenomics J. 2003;3:242-247.

Gelernter J, Kranzler HR, Satel SL, et al. Genetic association between dopamine transporter protein alleles and cocaine-induced paranoia. Neuropsychopharmacology. 1994; 11:195-200

Lott DC, Kim SJ, Cook EH, et al. Dopamine transporter gene associated with diminished subjective response to amphetamine. Neuropsychopharmacology 2005;30:602-9.

Zalsman G, Huang YY, Harkavy-Friedman JM, et al. Relationship of MAO-A promoter (u- VNTR) and COMT (V158M) gene polymorphisms to CSF monoamine metabolites levels in a psychiatric sample of Caucasians: a preliminary report. Am J Med Genet B Neuropsychiatr Genet 2005;132:100-3.

Guindalini C, Laranjeira R, Collier D, et al. Dopamine-beta hydroxylase polymorphism and cocaine addiction. Behav Brain Fund. 2008;4:1 -4.

Lohoff FW, Weller AE, Bloch PJ, et al. Association between the catechol-O-methyltransferase Val158Met polymorphism and cocaine dependence. Neuropsychopharmacology. 2008;33:3078-84.

Ito H, Hamajima N, Matsuo K, et al. Monoamine oxidase polymorphisms and smoking behaviour in Japanese. Pharmacogenetics. 2003;13:73-9.

Tsankova N, Renthal W, Kumar A, et al. Epigenetic regulation in psychiatric disorders. Nat Rev Neurosci 2007; 8:355-367.

Nestler EJ. The neurobiology of cocaine addiction. Sci Pract Perspect. 2005 Dec;3:4-10.

Hillemacher T, Fueling H, Hartl T, et al. Promoter specific methylation of the dopamine transporter gene is altered in alcohol dependence and associated with craving. J Psychiatr Res. 2009;43:388-92.